Researchers evaluated the immunogenicity and reactogenicity of COVID-19 mRNA vaccines in pregnant and lactating women compared with women who were not pregnant and those who were naturally infected with SARS-CoV-2 during pregnancy.
Pfizer and BioNTech announced positive results of a pivotal COVID-19 vaccine study that assessed efficacy of BNT162b2 in adolescents aged 12 to 15 years of age.
Polyethylene glycol (PEG) found in mRNA-based COVID vaccines, Pfizer and Moderna, have excluded patients due to risk of allergic reactions, including anaphylaxis; the recent approval of Janssen’s COVID-19 vaccine, which contains polysorbate, provides an alternative for this population.
New data about Pfizer COVID-19 efficacy after the first dose suggests high efficacy, raising questions about potential alternative dosing schedules.
Johnson & Johnson released interim analysis of its phase 3 EMSEMBLE trial for Ad.26.COV2, and provided more insight on overall protection in various countries, variant protection, and clinical outcomes.
We speak with Mildred Solomon, EdD, President of the Hastings Center and Professor of Global Health and Social Medicine at Harvard Medical School, where she directs the school’s Fellowship in Bioethics, about the COVID-19 pandemic, health equity, and vaccine distribution.
Moderna and Pfizer provide updates on mRNA vaccines against variant B.1.1.7; Infectious Diseases Society of America holds media briefing on COVID-19 variants.
Anthony Fauci, MD, discusses public trust in science, vaccine progress, and vaccine facilitation as the United States heads toward a new phase of the pandemic.
George Abraham, MD, offers insight into where the United States currently stands with regard to the COVID-19 pandemic, vaccine development, barriers to care in various patient populations, and the evolving roles of infectious disease specialists.
The COVID-19 Global Rheumatology Alliance Patient Experience Survey was used to assess the effect of antimalarial drug shortages during the COVID-19 pandemic.
